ATE219519T1 - Rekombinanttherapien für infektionen und hyperproliferative störungen - Google Patents
Rekombinanttherapien für infektionen und hyperproliferative störungenInfo
- Publication number
- ATE219519T1 ATE219519T1 AT97113730T AT97113730T ATE219519T1 AT E219519 T1 ATE219519 T1 AT E219519T1 AT 97113730 T AT97113730 T AT 97113730T AT 97113730 T AT97113730 T AT 97113730T AT E219519 T1 ATE219519 T1 AT E219519T1
- Authority
- AT
- Austria
- Prior art keywords
- host cell
- infections
- trans
- hyperproliferative disorders
- construct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30063789A | 1989-01-23 | 1989-01-23 | |
US46146190A | 1990-01-17 | 1990-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE219519T1 true ATE219519T1 (de) | 2002-07-15 |
Family
ID=26971882
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90902891T ATE174514T1 (de) | 1989-01-23 | 1990-01-22 | Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung |
AT97113730T ATE219519T1 (de) | 1989-01-23 | 1990-01-22 | Rekombinanttherapien für infektionen und hyperproliferative störungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90902891T ATE174514T1 (de) | 1989-01-23 | 1990-01-22 | Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung |
Country Status (5)
Country | Link |
---|---|
US (2) | US5861290A (de) |
JP (1) | JP2859252B2 (de) |
AT (2) | ATE174514T1 (de) |
DE (2) | DE69033975T2 (de) |
PT (1) | PT92931B (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245560B1 (en) * | 1990-01-18 | 2001-06-12 | The United States Of America As Represented By The Department Of Health And Human Services | Vector with multiple target response elements affecting gene expression |
EP0688358A4 (de) * | 1993-03-12 | 1997-10-01 | Univ Creighton | Verbesserte vektoren für die gentherapy |
US6995008B1 (en) * | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US20030190753A1 (en) * | 1995-11-09 | 2003-10-09 | Nature Technology Corporation | Vectors for gene transfer |
IL126714A (en) * | 1997-02-28 | 2010-12-30 | Enzo Therapeutics Inc | Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation |
US6479487B1 (en) * | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
US6413974B1 (en) * | 1998-02-26 | 2002-07-02 | Aventis Pharmaceuticals Inc. | 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6545140B1 (en) * | 1998-07-13 | 2003-04-08 | University Of Georgia Research Foundation, Inc. | DNA encoding an avian beta-defensin and uses thereof |
US6787154B2 (en) * | 1998-10-20 | 2004-09-07 | Salvatore Albani | Artificial antigen presenting cells |
AU774442B2 (en) | 1998-10-20 | 2004-06-24 | Salvatore Albani | Methods for isolation, quantification, characterization and modulation of antigen-specific T cells |
US7807377B2 (en) | 1998-10-20 | 2010-10-05 | Salvatore Albani | Method of isolating antigen-specific T cells employing artificial antigen presenting cells |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US6713293B1 (en) | 1999-02-08 | 2004-03-30 | Friedrich Grummt | Encapsulated cells containing an amplified expression vector as a drug delivery device |
US6869936B1 (en) * | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
US6399743B1 (en) | 1999-05-14 | 2002-06-04 | Dept. Of Veterans Affairs | Isolation and characterization of a rat epidermal growth factor related protein |
US20020034772A1 (en) * | 1999-06-29 | 2002-03-21 | Orlow Seth J. | Methods and compositions that affect melanogenesis |
US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
GB0008966D0 (en) * | 2000-04-13 | 2000-05-31 | Imp College Innovations Ltd | Vectors for gene therapy |
EP1322338A4 (de) * | 2000-10-04 | 2005-04-13 | Univ Pennsylvania | Zusammensetzungen und methoden zur verwendung des kapsidproteins aus flaviviren oder pestviren |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US20030170258A1 (en) * | 2001-05-09 | 2003-09-11 | Enzo Therapeutics, Inc. | Novel processes implementing selective immune down regulation (SIDR) |
US20030003074A1 (en) * | 2001-06-14 | 2003-01-02 | Macromed, Inc. | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
US20060159657A1 (en) * | 2001-06-14 | 2006-07-20 | Macromed, Incorporated | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
EP1281767A3 (de) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren |
WO2003030613A2 (en) * | 2001-10-05 | 2003-04-17 | Intermune, Inc. | Methods of treating liver fibrosis and hepatitis c virus infection |
US20030228261A1 (en) * | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
EP1369491A1 (de) * | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe |
US20040115254A1 (en) * | 2002-09-06 | 2004-06-17 | Genteric, Inc. | Microcapsules and methods of use |
BRPI0411526A (pt) * | 2003-06-18 | 2006-08-01 | Genelux Corp | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos |
GB0413702D0 (en) | 2004-06-18 | 2004-07-21 | Molmed Spa | Thymidine kinase |
CN101243184B (zh) * | 2005-08-16 | 2011-12-14 | 宝生物工程株式会社 | 用于治疗或预防免疫缺陷病毒感染的核酸 |
US7935342B2 (en) * | 2006-02-02 | 2011-05-03 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkB antagonist |
KR20080091838A (ko) * | 2006-02-02 | 2008-10-14 | 리나트 뉴로사이언스 코퍼레이션 | Trkb 작용제의 투여에 의한 원치않는 체중 감소 또는 섭식 장애의 치료 방법 |
US20090098529A1 (en) * | 2006-10-16 | 2009-04-16 | Nanhai Chen | Methods for attenuating virus strains for diagnostic and therapeutic uses |
MX2009006794A (es) * | 2006-12-20 | 2009-07-02 | Rinat Neuroscience Corp | Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes. |
WO2009037596A2 (en) | 2007-09-17 | 2009-03-26 | Barrick Gold Corporation | Method to improve recovery of gold from double refractory gold ores |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
JP6415977B2 (ja) | 2011-04-15 | 2018-10-31 | ジェネラックス・コーポレイションGenelux Corporation | 弱毒化ワクシニアウイルスのクローン株およびその使用方法 |
RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
KR101293620B1 (ko) | 2011-08-19 | 2013-08-13 | 국립암센터 | 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4405712A (en) * | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) * | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
FR2559159B1 (fr) * | 1984-02-02 | 1986-09-12 | Inst Nat Sante Rech Med | Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues |
US4663281A (en) * | 1984-03-22 | 1987-05-05 | Mass Institute Of Technology | Enhanced production of proteinaceous materials in eucaryotic cells |
US4738922A (en) * | 1984-05-25 | 1988-04-19 | Dana Farber Cancer Institute | Trans-acting transcriptional factors |
WO1986000922A1 (en) * | 1984-07-30 | 1986-02-13 | The Salk Institute For Biological Studies | Retroviral gene transfer vectors |
GB8424757D0 (en) * | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
US4725669A (en) * | 1984-11-09 | 1988-02-16 | President And Fellows Of Harvard College | Assay for detecting infection by human T-cell lymphotropic virus-III |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
WO1987000201A1 (en) * | 1985-07-05 | 1987-01-15 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
US4861719A (en) * | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
FR2606030B1 (fr) * | 1986-10-31 | 1989-10-20 | Pasteur Institut | Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci |
FR2606060B1 (fr) * | 1986-10-31 | 1992-02-28 | Wolf Philippe | Dispositif d'injection sous pression dans un corps, notamment en bois, poreux, fissure ou presentant des cavites |
EP0832981A1 (de) * | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten |
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US4980289A (en) * | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
US5026635A (en) * | 1987-05-19 | 1991-06-25 | Du Pont Merck Pharmaceutical | Stable human cell lines expressing an indicator gene product under virus-specific genetic controls |
DE3854313D1 (de) * | 1987-05-29 | 1995-09-21 | Dana Farber Cancer Inst Inc | Cis-Wirkung-Repressionen-Sequenzen, Cis-Wirkung-Antirepressionen-Sequenzen, Vektoren, Verfahren zur Vorbereitung und Anwendung. |
NZ225470A (en) * | 1987-07-21 | 1990-06-26 | Du Pont | Stable and viable recombinant viral vectors |
US5306631A (en) * | 1987-08-21 | 1994-04-26 | University Of Colorado Foundation, Inc. | Compositions and method for inhibition of HIV production |
WO1989001973A2 (en) * | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
US5175385A (en) * | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
US5246924A (en) * | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
EP0378576B1 (de) * | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduktionsveränderte fibroblasten und ihre anwendung |
US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
WO1989005349A1 (en) * | 1987-12-09 | 1989-06-15 | The Australian National University | Method of combating viral infections |
WO1989005345A1 (en) * | 1987-12-11 | 1989-06-15 | Whitehead Institute For Biomedical Research | Genetic modification of endothelial cells |
CA1315719C (en) * | 1988-02-05 | 1993-04-06 | Arthur Bank | Retroviral packaging cell lines and processes of using same |
CH684094A5 (de) * | 1988-03-21 | 1994-07-15 | Viagene Inc | Rekombinante Retroviren. |
WO1990001870A1 (en) * | 1988-08-22 | 1990-03-08 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Retroviral vectors expressing soluble cd4; a gene therapy for aids |
WO1990002806A1 (en) * | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
ATE118247T1 (de) * | 1988-09-27 | 1995-02-15 | Dana Farber Cancer Inst Inc | Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält. |
JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥hivプロウイルス、細胞系及びその使用 |
CA2489769A1 (en) * | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
DE4000286A1 (de) * | 1990-01-08 | 1991-07-11 | Bosch Gmbh Robert | Abschirmbehaeltnis fuer einen bereich einer leiterplatte |
AU7007491A (en) * | 1990-02-02 | 1991-08-08 | Schweiz. Serum- & Impfinstitut Bern | Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses |
CA2113990A1 (en) * | 1991-07-26 | 1993-02-18 | Frederick L. Moolten | Cancer therapy utilizing malignant cells |
-
1990
- 1990-01-22 AT AT90902891T patent/ATE174514T1/de not_active IP Right Cessation
- 1990-01-22 AT AT97113730T patent/ATE219519T1/de not_active IP Right Cessation
- 1990-01-22 DE DE69033975T patent/DE69033975T2/de not_active Expired - Fee Related
- 1990-01-22 DE DE69032841T patent/DE69032841T2/de not_active Expired - Fee Related
- 1990-01-23 PT PT92931A patent/PT92931B/pt not_active IP Right Cessation
-
1992
- 1992-10-22 US US07/965,039 patent/US5861290A/en not_active Expired - Fee Related
-
1995
- 1995-06-06 US US08/472,056 patent/US5837510A/en not_active Expired - Fee Related
-
1997
- 1997-11-20 JP JP9320199A patent/JP2859252B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69033975T2 (de) | 2002-10-02 |
ATE174514T1 (de) | 1999-01-15 |
PT92931B (pt) | 1996-03-29 |
DE69033975D1 (de) | 2002-08-01 |
JP2859252B2 (ja) | 1999-02-17 |
US5837510A (en) | 1998-11-17 |
DE69032841T2 (de) | 1999-05-12 |
PT92931A (pt) | 1990-07-31 |
US5861290A (en) | 1999-01-19 |
DE69032841D1 (de) | 1999-01-28 |
JPH10179181A (ja) | 1998-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE219519T1 (de) | Rekombinanttherapien für infektionen und hyperproliferative störungen | |
DE69400208D1 (en) | Olionukleotidalkylphosphonate und -phosphonothioate | |
ES2160707T3 (es) | Composiciones que comprenden agentes deteriorantes del adn y p53. | |
HK45193A (en) | Ozone decontamination of blood and blood products | |
GEP20002300B (en) | Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof | |
EP0335901A4 (en) | Methods and compositions for the treatment of non-ige-mediated diseases | |
ES2055427T3 (es) | Agente terapeutico. | |
HUP9702377A2 (hu) | Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek | |
BR9808100A (pt) | Utilização de amandantina para tratamento de hepatite c. | |
EP0733361A3 (de) | Verfahren zur Inaktivierung eingehüllter Viren und Spermien | |
NO953329D0 (no) | Rekombinante viruser og deres anvendelse i genterapien for behandling av öyesykdommer | |
DK312688A (da) | Glykkopeptid-antibiotika | |
DE68912155D1 (de) | Antivirales Kombinationspräparat. | |
WO1995015161A3 (de) | Arzneimittel zur behandlung der herzinsuffizienz | |
EP0552257A4 (en) | A plant protein useful for treating tumors and hiv infection | |
GR3033698T3 (en) | Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections. | |
DK0410749T3 (da) | Anthocyanidiner til behandling af ophthalmiske sygdomme | |
DE69122246T2 (de) | Identifikation von neuen medikamenten und reagenzien | |
FI885103A0 (fi) | Foerfarande foer saenkning av maengden kvaeveoxider under samtidig minimering av bildningen av andra foeroreningar. | |
SU1697755A1 (ru) | Способ лечени вазомоторного риносинуита | |
SU936919A1 (ru) | Способ лечени гнойных ран | |
NO952212L (no) | Preparater inneholdende acyclovirlignende forbindelser og 2'-vinylsubstituerte nukleosidanaloger for behandling av virale infeksjoner | |
MY109685A (en) | Method for treating hepatitis b carriers with minimal disease | |
FR1342884A (fr) | Procédé de contrôle biologique spécifique rapide de l'efficaité des vaccins et s'rums anti-virus respiratoires | |
RU92016478A (ru) | Способ диагностики гепатита, способ лечения гепатита |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |